We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

160 hedge funds and large institutions have $1.78B invested in Syndax Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 65 increasing their positions, 41 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 10

59% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 41

28% more capital invested

Capital invested by funds: $1.39B → $1.78B (+$393M)

15% more funds holding

Funds holding: 139 → 160 (+21)

10% more funds holding in top 10

Funds holding in top 10: 10 → 11 (+1)

8% more call options, than puts

Call options by funds: $2.77M | Put options by funds: $2.56M

0.59% more ownership

Funds ownership: 105.87% → 106.47% (+0.59%)

Holders
160
Holders Change
+21
Holders Change %
+15.11%
% of All Funds
2.57%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.18%
New
32
Increased
65
Reduced
41
Closed
10
Calls
$2.77M
Puts
$2.56M
Net Calls
+$203K
Net Calls Change
-$4.79M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$83.9M
2
State Street
State Street
Massachusetts
+$24M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$21.5M
4
PBA
Paradigm Biocapital Advisors
New York
+$20.3M
5
Barclays
Barclays
United Kingdom
+$16M

Top Sellers

1
WP
Woodline Partners
California
-$19M
2
HM
HealthCor Management
New York
-$18.4M
3
6CM
683 Capital Management
New York
-$13.1M
4
NCM
Nantahala Capital Management
Connecticut
-$9.32M
5
BI
BVF Inc
California
-$8.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
51
UBS Group
Switzerland
$4.4M -$2.63M -112,747 -39%
Norges Bank
52
Norges Bank
Norway
$4.3M -$445K -19,100 -10%
D.E. Shaw & Co
53
D.E. Shaw & Co
New York
$4.08M +$756K +32,407 +25%
GTC
54
Ghost Tree Capital
New York
$3.82M -$1.17M -50,000 -25%
Morgan Stanley
55
Morgan Stanley
New York
$3.8M -$215K -9,202 -6%
N
56
Nuveen
North Carolina
$3.69M -$490K -21,015 -13%
Prudential Financial
57
Prudential Financial
New Jersey
$3.55M +$793K +34,005 +32%
Swiss National Bank
58
Swiss National Bank
Switzerland
$3.29M +$376K +16,100 +14%
TCM
59
Tekla Capital Management
Massachusetts
$3M +$2.75M +117,717 New
AllianceBernstein
60
AllianceBernstein
Tennessee
$2.77M – – –
AAA
61
Affinity Asset Advisors
New York
$2.54M +$2.33M +100,000 New
Alyeska Investment Group
62
Alyeska Investment Group
Illinois
$2.54M +$2.33M +100,000 New
VOYA Investment Management
63
VOYA Investment Management
Georgia
$2.41M – – –
Renaissance Technologies
64
Renaissance Technologies
New York
$2.07M +$1.89M +81,200 New
RhumbLine Advisers
65
RhumbLine Advisers
Massachusetts
$2.05M +$41.5K +1,780 +2%
AG
66
Algert Global
California
$1.98M +$674K +28,880 +59%
HM
67
HealthCor Management
New York
$1.78M -$18.4M -789,240 -92%
GTCM
68
Gyon Technologies Capital Management
New Jersey
$1.74M +$822K +35,226 +107%
California State Teachers Retirement System (CalSTRS)
69
California State Teachers Retirement System (CalSTRS)
California
$1.73M +$135K +5,768 +9%
CM
70
Crestline Management
Texas
$1.63M +$15.3K +656 +1%
SFI
71
Susquehanna Fundamental Investments
Pennsylvania
$1.57M +$379K +16,270 +36%
UBS AM
72
UBS AM
Illinois
$1.48M +$345K +14,792 +34%
BNP Paribas Financial Markets
73
BNP Paribas Financial Markets
France
$1.42M -$244K -10,465 -16%
CS
74
Credit Suisse
Switzerland
$1.39M +$220K +9,443 +21%
State of Wisconsin Investment Board
75
State of Wisconsin Investment Board
Wisconsin
$1.36M +$169K +7,234 +16%
1 2
3
4 5

SNDX Hedge Fund Activity: Q4 2022 in Review

160 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2022, worth a combined $1.78B — up 28% from $1.39B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new SNDX positions and 10 closed out — a net gain of 22 holders — while 65 added to existing stakes and 41 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $83.9M. The largest seller was Woodline Partners, exiting entirely with an estimated $19M sold.

  • 160 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2022, up from 139 in Q3 2022.
  • Funds reported $1.78B of Syndax Pharmaceuticals stock for Q4 2022, up 28% quarter-over-quarter.
  • 32 funds opened new Syndax Pharmaceuticals positions in Q4 2022 and 10 closed out, a net change of +22 holders.
  • The largest Syndax Pharmaceuticals buyer in Q4 2022 was Wellington Management Group, an estimated $83.9M added.
  • The largest Syndax Pharmaceuticals seller in Q4 2022 was Woodline Partners, an estimated $19M sold.

Based on aggregated 13F filings for Q4 2022.